Form 4 for WALD Waldencast plc
Accepted 2026-08-07 16:10:23 ET · period of report 2026-07-30 · accession 0001840199-26-000091 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 16:10 | 2026-07-30 | WALD | Manfredi Manuel | CFO | M - OptEx | $0.00 | +79.3K | 118.9K | +200% | $0 |
| D | 2026-08-07 16:10 | 2026-07-30 | WALD | Manfredi Manuel | CFO | M - OptEx | $0.00 | -79.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2026-07-30 | M | A | 79,289 | $0.00 | 118,933 | D | — | — | (F1) Represents accelerated vesting of 79,289 outstanding restricted stock units ("RSUs") held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical. |
| 2 | Derivative | Restricted Stock Units | 2026-07-30 | M | D | 79,289 | $0.00 | 0 | D | — · — to — | 79,289 Class A Ordinary Shares | (F2) Each RSU represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election. (F1) Represents accelerated vesting of 79,289 outstanding restricted stock units ("RSUs") held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical. (F3) On October 30, 2024, the reporting person was granted 118,933 RSUs, which would have vested over a three-year period as follows: (i) 39,644 on October 1, 2025; (ii) 39,644 on October 1, 2026; and (iii) 39,645 on October 1, 2027. (F3) On October 30, 2024, the reporting person was granted 118,933 RSUs, which would have vested over a three-year period as follows: (i) 39,644 on October 1, 2025; (ii) 39,644 on October 1, 2026; and (iii) 39,645 on October 1, 2027. |